2017 American Society of Hematology Annual Meeting*

Download All
December 9-12, 2017; Atlanta, Georgia
Farhad Ravandi, MD, and B. Douglas Smith, MD, review and share their expert perspectives on key findings in leukemia presented at the 2017 ASH annual meeting.
Farhad Ravandi, MD
B Douglas Smith
B. Douglas Smith, MD


Review promising preliminary findings from a phase I/II trial assessing combination therapy with inotuzumab ozogamicin and bosutinib in patients with relapsed/refractory Philadelphia chromosome–positive ALL or CML in lymphoid blast phase.

Released: December 12, 2017

No clear evidence of benefit associated with midostaurin maintenance therapy in this unplanned post hoc subset analysis of the RATIFY trial.

Released: December 13, 2017

Observational study found that a TKI duration of 5.8 years and MR4 duration of 3.1 years decreased the likelihood of relapse for patients with CML discontinuing TKI therapy.

Released: December 12, 2017

Azacitidine was well tolerated and significantly improved disease-free survival in older patients with anemia-refractory AML.

Released: December 18, 2017

Results confirm strong prognostic value of NPM1/FLT3-ITD genotypes in AML, supporting 2017 ELN risk stratification criteria that include FLT3-ITD allelic burden.

Released: December 14, 2017

Preliminary data suggest novel combination of gilteritinib and chemotherapy has antileukemic effect in FLT3-mutated AML with acceptable safety.

Released: December 13, 2017

Ivosidenib, an investigational mutant IDH1 inhibitor, was well tolerated with evidence of activity and durable responses in patients with malignancies harboring mutated IDH1.

Released: December 20, 2017

The combination of IDH inhibitors enasidenib or ivosidenib with standard 7 + 3 induction chemotherapy appears safe with response rates comparable to those expected with standard induction chemotherapy in patients with either de novo or secondary AML.

Released: December 15, 2017

Study reported median event-free survival of 8.3 months in patients receiving nivolumab plus cytarabine and idarubicin with manageable safety profile.

Released: December 19, 2017

After more than 1 year of follow-up, the combination of venetoclax plus low-dose cytarabine achieved a CR + CRi rate of 62% and a median OS of 11.4 months in elderly patients with AML who are unfit for chemotherapy.

Released: December 18, 2017

Preliminary findings demonstrate that the CPX-351 liposomal formulation of cytarabine:daunorubicin is both safe and active at reduced and higher doses in patients with AML at high risk for death during induction chemotherapy.

Released: December 18, 2017

Combining peginterferon-alfa 2a with nilotinib in patients with chronic-phase CML showed significantly better rates of deep molecular response than nilotinib alone.

Released: December 19, 2017

Ponatinib combined with steroids yielded a 90% complete hematologic response and reasonable tolerability profile at Week 24 in unfit and elderly patients with Philadelphia chromosome–positive ALL.

Released: December 20, 2017

In this expert analysis, Farhad Ravandi, MD, and B. Douglas Smith, MD, review the clinically relevant studies on the management of acute and chronic leukemias presented at the Hematology 2017 annual meeting.

Farhad Ravandi, MD B Douglas Smith B. Douglas Smith, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: February 23, 2018 Expired: No longer available for credit

This large prospective study shows that identification of residual leukemia by targeted next-generation sequencing of select mutations present in CR serves as a strong independent predictor for AML relapse and survival.

Released: December 14, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Celgene Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics Inc.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings